[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cholelithiasis-associated-with-common-bile-duct-stones\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cholelithiasis-associated-with-common-bile-duct-stones":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,66],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100631010","prophylactic-ps-placement-to-prevent-pancreatitis-after-endoscopic-transpapillary-gpc-for-cholelithiasis-with-concomitant-choledocholithiasis-100631010",false,"NCT07495111","Prophylactic PS Placement to Prevent Pancreatitis After Endoscopic Transpapillary GPC for Cholelithiasis With Concomitant Choledocholithiasis","Prophylactic Pancreatic Stent Placement to Prevent Pancreatitis After Endoscopic Transpapillary Gallbladder-preserving Cholecystolithotomy for Cholelithiasis With Concomitant Choledocholithiasis","Inclusion Criteria:\n\n1. Patients aged 18 years or older;\n2. Patients with gallbladder stones and common bile duct (CBD) stones confirmed by ultrasound and\u002For MRCP or other imaging modalities (CT\u002FMRI);\n3. Patients with every gallbladder stone ≤1 cm in diameter or sludge-like stones;\n4. Patients without a history of gastrointestinal reconstruction surgery,cholecystectomy or previous biliary surgery, includes ERCP;\n5. The morphology and size of the gallbladder are essentially normal and the thickness of the gallbladder wall is ≤3 mm;\n6. Patients with at least one of the following high-risk factors for post-ERCP pancreatitis (PEP): suspected sphincter of Oddi dysfunction (SOD), female sex, history of pancreatitis, difficult cannulation (defined as ≥5 cannulation attempts or ≥5 minutes of cannulation time), pancreatic duct contrast injection, age \\\u003C35 years, non-dilated extrahepatic bile duct, no history of chronic pancreatitis, normal serum bilirubin, precut sphincterotomy, biliary balloon dilation, incomplete bile duct stone clearance, or intraductal ultrasound ;\n7. Patients who voluntarily provide signed informed consent.\n\nExclusion Criteria:\n\n1. Patients with any of the following diagnoses: chronic atrophic cholecystitis, porcelain gallbladder, suspected gallbladder malignancy, or Mirizzi syndrome;\n2. Patients with ectopic duodenal papilla or congenital pancreaticobiliary malformations;\n3. Patients unfit for ERCP endoscopic treatment due to severe systemic diseases;\n4. Patients with severe coagulation dysfunction (defined as an International Normalized Ratio \\[INR\\] \\>1.5) or significant thrombocytopenia (platelet count \\\u003C50×10⁹\u002FL);\n5. Pregnant women;\n6. Patients with guidewire entry into the pancreatic duct ≥3 times during the procedure;\n7. Patients with allergies to aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs);\n8. Patients with congenital or acquired absence of the rectum;\n9. Patients with severe acute pancreatitis","ALL","18 Years",{"count":19,"type":20},88,"ESTIMATED","INTERVENTIONAL",[23],"NA","In this multicenter, randomized trial, patients with cholelithiasis with concomitant choledocholithiasis based on inclusion and exclusion criteria will be randomly assigned to receive rectal indomethacin alone or the combination of indomethacin plus a prophylactic pancreatic stent after endoscopic transpapillary gallbladder-preserving cholecystolithotomy.Clinical data and patient-reported outcomes are regularly collected at baseline and during follow-up periods. The study aims to analyze the impact of pancreatic duct stent implantation on the incidence of post-ERCP pancreatitis in gallstone patients treated with ERCP-GPC by comparing the efficacy differences between the experimental and control groups. Additionally, the study investigate the effects of pancreatic duct stent placement post-ERCP on other postoperative complications, conduct a comparative analysis of the economic benefits of placing versus not placing pancreatic duct stents after ERCP, and develop effective clinical strategies for preventing pancreatitis after gallbladder-preserving stone extraction in gallstone patients.",[26],"Cholelithiasis Associated With Common Bile Duct Stones",[28,29,30,31],"Cholelithiasis with Concomitant Choledocholithiasis","Endoscopic Transpapillary Gallbladder-preserving Cholecystolithotomy","post-ERCP pancreatitis","Randomized Controlled Trial (RCT)","RECRUITING","2026-05-14",{"date":35,"type":36},"2026-05-18","ACTUAL",{"date":38,"type":36},"2025-12-01",{"date":40,"type":20},"2028-06",{"name":42,"class":43},"Qilu Hospital of Shandong University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":54,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":61,"startDateStruct":62,"completionDateStruct":63,"leadSponsor":65,"locationsCount":44},"100624702","treatment-outcomes-and-complications-of-three-therapeutic-approaches-for-concomitant-choledocholithiasis-and-cholecystolithiasis-100624702","NCT07413068","Treatment Outcomes and Complications of Three Therapeutic Approaches for Concomitant Choledocholithiasis and Cholecystolithiasis","Comparative Study of ERCP, ERCP Plus Laparoscopic Cholecystectomy, and Conservative Management in Patients With Concomitant Choledocholithiasis and Cholecystolithiasis.","Inclusion Criteria\n\n1. Patients over the age of 18 years;\n2. Ultrasound, MRCP, or other imaging examination findings (CT\u002FMRI) clearly indicate a diagnosis of cholelithiasis with concomitant choledocholithiasis;\n3. Patients with no history of gastrointestinal reconstruction surgery or cholecystectomy or previous biliary tract surgery (include history of ERCP);\n4. Patients with every gallbladder stone ≤1 cm in diameter or sludge-like stones;\n5. The morphology and size of the gallbladder are essentially normal and the thickness of the gallbladder wall is ≤3 mm;\n6. Voluntary provision of signed informed consent.\n\nExclusion Criteria\n\n1. Atrophic cholecystitis; porcelain gallbladder; suspect malignant tumor of the gallbladder; stenosis of the lower segment of the common bile duct; Mirrizzi syndrome;\n2. Unable to undergo endoscopic interventions for various reasons;\n3. Absolute surgical contraindications, including severe hepatic, renal, cardiac and pulmonary insufficiency, history of cerebral coma and allergy to anesthesia, etc;\n4. Presence of ectopic duodenal papilla or congenital pancreaticobiliary malformation;\n5. Patients with severe coagulopathy, defined as an International Normalized Ratio (INR) \\> 1.5 or patients with significant thrombocytopenia (platelet count \\\u003C 50 × 10⁹\u002FL);\n6. Pregnant women;",{"count":53,"type":20},300,"36 Months","OBSERVATIONAL","Recruit patients with cholelithiasis with concomitant choledocholithiasis into the cohort, and assign them to undergo endoscopic transpapillary gallbladder-preserving cholecystolithotomy or ERCP plus laparoscopic cholecystectomy or conservative treatment based on patient preference. Collect clinical data and patient-reported outcomes regularly at baseline and during follow-up in the cohort. Assess the clinical safety of ERCP-GPC and LC by evaluating the clinical success rate of treatment as well as the incidence of short-term and long-term postoperative complications; investigate the efficacy differences among endoscopic transpapillary gallbladder-preserving cholecystolithotomy or ERCP plus laparoscopic cholecystectomy or conservative treatment in managing cholelithiasis with concomitant choledocholithiasis.",[26],[28,29,59,60],"ERCP plus Laparoscopic Cholecystectomy","Conservative treatment",{"date":35,"type":36},{"date":38,"type":36},{"date":64,"type":20},"2030-12",{"name":42,"class":43},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":44},"100632741","optimal-timings-of-laparoscopic-cholecystectomy-after-ercp-in-patients-with-gallstones-along-with-cbd-stones-100632741","NCT07517627","Optimal Timings of Laparoscopic Cholecystectomy After ERCP in Patients With Gallstones Along With CBD Stones","Comparative Analysis of Early Versus Delayed Laparoscopic Cholecystectomy After Endoscopic Retrograde Cholangiopancreatography (ERCP) in Patients of Cholelithiasis With Choledocholithiasis","ED-LC","Inclusion criteria\n\n* Patients diagnosed with cholelithiasis with choledocholithiasis based on clinical and radiological findings (right subcostal pain, presence of gallstones, and dilated common bile duct on ultrasound and MRCP)\n* Age 14 to 70 years\n* Both males and females\n* Duration of symptoms less than 3 days\n* Presence of common bile duct stone with successful clearance on ERCP\n\nExclusion Criteria\n\n* Features suggestive of malignancy on imaging\n* Patients who develop severe pancreatitis after ERCP","14 Years","70 Years",{"count":77,"type":20},40,[23],"This randomized controlled trial aims to compare the mean operative time and outcomes of early versus delayed laparoscopic cholecystectomy after ERCP in patients with cholelithiasis and choledocholithiasis. Patients will be randomized into two groups: early cholecystectomy (within 72 hours of ERCP) and delayed cholecystectomy (≥1 month after ERCP). Outcomes include operative time, intra-operative blood loss, hospital stay, and conversion to open cholecystectomy",[26],"2026-04-03",{"date":83,"type":36},"2026-04-08",{"date":85,"type":36},"2025-05-05",{"date":87,"type":20},"2026-10",{"name":89,"class":43},"Rija Zainab"]